112799-19-6

Usage

Uses

Used in Pharmaceutical and Medicinal Chemistry:
4-(piperidin-1-yl)tetrahydro-2H-pyran-4-carbonitrile is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a promising candidate for the development of new drugs, particularly in the treatment of neurological disorders, due to its potential to interact with specific receptors or enzymes.
Used in Organic Chemistry Research:
4-(piperidin-1-yl)tetrahydro-2H-pyran-4-carbonitrile serves as a subject of study for researchers in the field of organic chemistry. Its synthesis and characterization can provide insights into the reactivity and properties of heterocyclic compounds, contributing to the advancement of organic synthesis methods and the discovery of new chemical reactions.
Used in Drug Design and Development:
In the pharmaceutical industry, 4-(piperidin-1-yl)tetrahydro-2H-pyran-4-carbonitrile is used as a building block for the design and development of novel drug candidates. Its unique structure can be further modified or functionalized to create new compounds with improved pharmacological properties, such as increased potency, selectivity, or bioavailability.
Used in Chemical Synthesis:
4-(piperidin-1-yl)tetrahydro-2H-pyran-4-carbonitrile can be used as a starting material or intermediate in the synthesis of various organic compounds, including natural products, agrochemicals, and specialty chemicals. Its versatile structure allows for a wide range of chemical reactions, enabling the preparation of diverse chemical libraries for screening and optimization.

Upstream product

• 110-89-4 piperidine 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 151-50-8 potassium cyanide 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 
• 112799-02-7 4-Trimethylsilanyloxy-tetrahydro-pyran-4-carbonitrile 
• 50289-10-6 4-hydroxy-tetrahydropyran-4-carbonitrile 

Relevant academic research and scientific papers

The low affinity PCP sites in the rat cerebellum not only bind TCP-like but also BTCP-like structures

Congeners of the potent dopamine (DA) re-uptake inhibitor l-[1-(2- benzo[b]thiophenyl)cyclohexyl]piperidine (BTCP) are unexpectedly able to bind in the rat cerebellum, although this structure is devoid of dopaminergic nerve endings. In line with previous studies the hypothesis that they bind to low affinity PCP sites labelled with [3H]TCP in the rat cerebellum, even though they do not bind to the high affinity PCP sites in the forebrain, was considered. Analogues of l-[1-(2-thiophenyl)cyclohexyl]piperidine (TCP) and BTCP with a modified aromatic moiety and with O or S atoms substituted in the cyclohexyl ring were prepared and tested in competition experiments both in rat forebrain and cerebellum membranes labelled with [3H]TCP, and in rat striatum membranes labelled with [3H]BTCP. Results indicated that BTCP and congeners could bind to low affinity PCP sites labelled with [3H]TCP in the rat cerebellum with a decrease of the selectivity for the DA transporter. On the contrary, some TCP analogues displayed a very high selectivity for these low affinity sites: they might be important pharmacological tools to elucidate the nature and function at yet unknown of these sites. (C) 2000 Editions scientifiques et medicales Elsevier SAS.

The search for TCP analogues binding to the low affinity PCP receptor sites in the rat cerebellum

With the aim of obtaining selective ligands of the low affinity binding sites of [3H]-1-[1-(2-thienyl)cyclohexyl]piperidine ([3H]TCP) in the rat cerebellum, oxygen and sulfur atoms were introduced in the TCP structure and derivatives to obtain analogues with a lowered lipophilicity. These compounds, and others already obtained, were assayed comparatively to determine their affinities for three sites labeled with [3H]TCP: one in the forebrain, the originally described PCP receptor, and two in the rat cerebellum. Lowering the lipophilicity and modifying the hetero-aromatic moiety yielded some ligands with increased affinity for the low affinity sites in the rat cerebellum and decreased affinity for the high affinity sites in the forebrain. Particularly, two compounds displaying both a high affinity and a good selectivity might be valuable tools to elucidate the pharmacology of the low affinity PCP sites labeled with [3H]TCP in the rat cerebellum.

Effect of lowered lipophilicity on the affinity of PCP analogues for the PCP receptor and the dopamine transporter

Oxygen and sulphur atoms were introduced in the cyclohexyl and piperidinyl moieties of the basic structures 1-(1-phenyl-cyclohexyl)piperidine (PCP), 1- [1-(2-thienyl)cyclohexyl]piperidine (TCP), and 1-[1-(2- benzo[b]thiophenyl)cyclohexyl]piperidine (BTCP) to lower their global lipophilicity. The compounds obtained were tested comparatively for their affinity for the PCP receptor labelled with [3H]TCP and for the dopamine (DA) transporter labelled with [3H]BTCP. Lowering the global lipophilicity in PCP and TCP series is detrimental to the affinity and selectivity for the PCP receptor. In the BTCP series lowering of the global lipophilicity is less deleterious and may, on the contrary, be a useful way of increasing selectivity for the DA transporter in some instances.